CLL Microlearning Video Series
This microlearning series explores practical, evidence-based insights for managing CLL in the modern era. Across eight short-format video segments, an APP specializing in CLL care shares how to tailor treatment decisions, optimize zanubrutinib use, manage toxicities, and empower patients through education and partnership. Together, these videos equip oncology clinicians with the tools to confidently deliver personalized, patient-centered CLL care.
For APPs, pharmacists, nurses and care teams managing patients with Chronic Lymphocytic Leukemia (CLL), the landscape is evolving fast. From new therapies to refined patient-selection strategies, staying current is critical. This micro-learning video library lets you access short, targeted modules your team can apply in real-time practice.
What you’ll learn:
-
What patient- and disease-specific factors should be considered in CLL treatment?
-
When and how to initiate frontline therapy?
-
Where does Zanubrutinib fit into the therapy landscape?
-
How to monitor and manage side-effects in real-world practice?
Designed for advanced practice providers, oncology pharmacists and multidisciplinary teams, each video is under 10 minutes so you can learn on-the-go. Get started below.
Video Library
Understanding patient- and disease-specific factors such as comorbidities, genomic testing, and lifestyle helps guide optimal treatment selection. Shared decision-making ensures therapy aligns with clinical and personal goals.
Treatment should begin when CLL becomes symptomatic or meets iwCLL criteria. Recognizing signs like cytopenias and bulky nodes ensures timely and appropriate therapy initiation.
Zanubrutinib’s high selectivity offers strong efficacy with fewer off-target effects compared to earlier BTK inhibitors, improving tolerability and outcomes—especially in patients with comorbidities.
Flexible dosing and manageable adjustments make zanubrutinib adaptable for diverse patient needs. APPs play a key role in counseling patients to promote adherence and safe dose modification.
Proactive monitoring and patient education on mild side effects—like bruising, GI upset, or rash—support adherence and improve long-term treatment success.
With a lower incidence of atrial fibrillation than other BTK inhibitors, zanubrutinib offers a safer option for patients with cardiac disease. APPs should coordinate monitoring and care with cardiology.
Adherence and open communication are vital for ongoing CLL control. APPs foster trust, address barriers, and personalize care to sustain long-term treatment engagement.
Clinical experience highlights zanubrutinib’s role in improving tolerability and maintaining effective therapy. Continuous learning and collaboration help optimize CLL management for each patient.
Related Content
PQI: Patient Screening for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The purpose of this PQI is to assess the individualized characteristics of the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patient and important screening measures in order to achieve optimal pharmacological therapy.
March 25, 2025 | 7:34 PM
Toolkit: Optimize CLL Care in Epic
The Epic EMR Toolkit helps clinicians and care teams harness the full potential of Epic’s reporting and clinical decision support tools to simplify patient management.
November 5, 2025 | 4:08 PM
Video: BRUKINSA® (Zanubrutinib) for Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
The discussion provides key insights into clinical trial data, safety, dosing, and real-world patient management considerations, making it a valuable resource for oncology pharmacy professionals and care teams.
May 3, 2023 | 5:51 PM